-
1 Comment
Kissei Pharmaceutical Co., Ltd is currently in a long term uptrend where the price is trading 11.5% above its 200 day moving average.
From a valuation standpoint, the stock is 99.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.7.
Kissei Pharmaceutical Co., Ltd's total revenue rose by 17.1% to $20B since the same quarter in the previous year.
Its net income has increased by 46.8% to $2B since the same quarter in the previous year.
Based on the above factors, Kissei Pharmaceutical Co., Ltd gets an overall score of 4/5.
| Exchange | F |
|---|---|
| CurrencyCode | EUR |
| Sector | |
| ISIN | None |
| Industry |
| PE Ratio | 9.02 |
|---|---|
| Market Cap | 833M |
| Beta | 0.24 |
| Target Price | None |
| Dividend Yield | 2.4% |
Kissei Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products primarily in Japan. It offers Urief and Urief OD tablets for the treatment of dysuria; Glufast, Glubes, and Marizev tablets for type 2 diabetes; Darbepoetin Alfa BS and Epoetin Alfa BS injections for the treatment of renal anemia; Beova tablets for overactive bladder treatment; P-TOL chewable tablets for treating hyperphosphatemia; and Minirin Melt OD tablets for nocturia due to nocturnal polyuria in males, central diabetes insipidus, and nocturnal enuresis resulted from decrease of urine osmolality. The company's products in pipeline include KPS-0373 that has completed Phase III clinical trial to treat spinocerebellar ataxia; CCX168, which has completed Phase III clinical trial for the treatment of microscopic polyangiitis and granulomatosis with polyangiitis; AJM300, which is in Phase III clinical trial to treat ulcerative colitis; R788 that is in Phase III clinical trial to treat chronic idiopathic thrombocytopenic purpura; and MR13A9, which is in Phase III clinical trial to treat uremic pruritus in dialysis patients. It is also developing KLH-2109 for treating endometriosis and uterine fibroids; KDT-3594 for the treatment of Parkinson's disease; Silodosin for dysuria associated with benign prostatic hyperplasia; Mitiglinide for type 2 diabetes mellitus; and Bedoradrine for the treatment of acute exacerbation of asthma. In addition, it develops and sells protein controlled and energy supply foods; and purchases and sells related materials, as well as offers system development and information processing, construction contracting, equipment and facility management, and information gathering and development support services. The company was formerly known as Kissei Yakuhin Kogyo Co., Ltd. and changed its name to Kissei Pharmaceutical Co., Ltd. in October 1964. The company was founded in 1946 and is headquartered in Matsumoto, Japan.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for KIS.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
